Predictors of treatment failures during chemotherapy: A prospective study on 110 older cancer patients

Marinello, Renata; Marenco, Daniela; Roglia, D.; Stasi, M; Ferrando, Alberto; Ceccarelli, Manuela; Bertetto, Oscar; Molaschi, M; Ciccone, Giovannino

doi:10.1016/j.archger.2008.01.011

Cited by 36 publications

(50 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chemotherapy feasibility rates were consistent with previous studies, which ranged from 49.1% [19,20,23,43,[45][46][47][48] to 80% [49]. The highest feasibility rates were found in studies [19,20,49] that included only patients without metastases, whose functional status was probably better than in our population.…”

Section: Discussionsupporting

confidence: 79%

Assessment of Solid Cancer Treatment Feasibility in Older Patients: A Prospective Cohort Study

Laurent

Paillaud

Tournigand³

et al. 2014

The Oncologist

View full text Add to dashboard Cite

Purpose. To assess solid cancer treatment feasibility in older patients Methods. Between 2007 and 2010, 385 consecutive elderly patients (mean age: 78.9 6 5.4 years; 47.8% males) with solid malignancies referred to two geriatric oncology clinics were included prospectively. We recorded feasibility of first-line chemotherapy (planned number of cycles in patients without metastases and three to six cycles depending on tumor site in patients with metastases), surgery (patient alive 30 days after successfully performed planned surgical procedure), radiotherapy (planned dose delivered), and hormonal therapy (planned drug dose given), and we recorded overall 1-year survival. Results. Main tumor sites were colorectal (28.6%), breast (23.1%), and prostate (10.9%), and 47% of patients had metastases. Planned cancer treatment was feasible in 65.7% of patients with metastases; this proportion was 59.0% for chemotherapy, 82.6% for surgery, 100% for radiotherapy, and 85.2% for hormonal therapy. In the group without metastases, feasibility proportions were 86.8% overall, 72.4% for chemotherapy, 95.7% for surgery, 96.4% for radiotherapy, and 97.9% for hormonal therapy. Factors independently associated with chemotherapy feasibility were good functional

show abstract

Section: Discussionsupporting

confidence: 79%

Assessment of Solid Cancer Treatment Feasibility in Older Patients: A Prospective Cohort Study

Laurent

Paillaud

Tournigand³

et al. 2014

The Oncologist

View full text Add to dashboard Cite

show abstract

“…For comorbidity, initial analysis revealed that only 6 out of 16 studies found an association with mortality (38%). However, when subdividing according to the assessment method used, only one out of five studies using the Charlson comorbidity index [38] and none of the four studies using the number of comorbid conditions found an association, while four out of five studies using the Cumulative Illness Rating Scale for Geriatrics (CIRS-G) found comorbidity to be associated with mortality (80%) [33,50,53,60,65]. For one study, the results for comorbidity were not clearly reported.…”

Section: All-cause Mortalitymentioning

confidence: 99%

“…For completion of chemotherapy, impaired cognitive function was found to be associated with less completion or the need for dose reduction in two out of three studies (66%, 53,58] found that comorbidity was predictive of lower completion rates (60%). Two of these used the CIRS-G and one the Charlson comorbidity index to assess comorbidity; the two studies that did not find an association both used the Charlson comorbidity index.…”

Section: Chemotherapy Completionmentioning

confidence: 99%

The Value of Geriatric Assessments in Predicting Treatment Tolerance and All-Cause Mortality in Older Patients With Cancer

Hamaker¹,

et al. 2012

View full text Add to dashboard Cite

After completing this course, the reader will be able to:1. Describe the predictive value of geriatric assessments for survival in older cancer patients.2. Describe the predictive value of geriatric assessments for treatment tolerance (such as toxicity of chemotherapy and perioperative complications) in older cancer patients. Explain the concept of frailty compared to individual geriatric conditions.This article is available for continuing medical education credit at CME.TheOncologist.com. CME CME ABSTRACTBackground. Awareness of the use of geriatric assessments for older patients with cancer is increasing. The aim of this review is to summarize all available evidence on the association between geriatric assessments and relevant oncologic outcomes. Method. A systematic search was conducted in Medline and Embase of studies on geriatric assessment in oncology, focusing on the association between baseline assessment and outcome.Results. The literature search identified 2008 reports; 51 publications from 37 studies were selected for inclu-

show abstract

“…The program may therefore overestimate the benefit of chemotherapy in unfit older women, whose benefit may be substantially negated by competing health risks and/or treatment toxicity [47]. Functional status and patient comorbid illness have been found to be strong independent predictors of adverse outcomes from chemotherapy [48]. It is thus imperative that a complex geriatric assessment be done in establishing whether an older woman with breast cancer will tolerate and benefit from adjuvant systemic therapy, including targeted agents.…”

Section: Elderly Women and Adjuvant Chemotherapy And Targeted Treatmentmentioning

confidence: 99%

Early Breast Cancer in the Older Woman

Gandhi

Verma

2011

The Oncologist

View full text Add to dashboard Cite

Background. Women aged >65 are generally underrepresented in early breast cancer studies. Therefore, the optimal management of this group of women remains less certain.Methods. A literature review of recently published trials, reviews, and practice guidelines outlining the surgical and adjuvant management of early breast cancer in older women was performed.Results. Surgery remains as the cornerstone treatment for early breast cancer in the elderly. Adjuvant radiation is generally considered if the projected lifespan is >5 years. Hormone receptor-positive disease is best treated with adjuvant endocrine treatment; aromatase inhibitors and tamoxifen are both options. Evidence for the use of adjuvant

show abstract

Predictors of treatment failures during chemotherapy: A prospective study on 110 older cancer patients

Cited by 36 publications

References 26 publications

Assessment of Solid Cancer Treatment Feasibility in Older Patients: A Prospective Cohort Study

Assessment of Solid Cancer Treatment Feasibility in Older Patients: A Prospective Cohort Study

The Value of Geriatric Assessments in Predicting Treatment Tolerance and All-Cause Mortality in Older Patients With Cancer

Early Breast Cancer in the Older Woman

Contact Info

Product

Resources

About